Hyloris Pharmaceuticals SA (HYL.BR)
EUR 5.8
(-1.36%)
EUR 5.8
(-1.36%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 344 Thousand EUR | -53.95% |
| 2022 | 747 Thousand EUR | 82.64% |
| 2021 | 409 Thousand EUR | -94.88% |
| 2020 | 7.99 Million EUR | 36222.73% |
| 2019 | 22 Thousand EUR | -99.76% |
| 2018 | 9.3 Million EUR | 37.28% |
| 2017 | 6.78 Million EUR | 174.42% |
| 2016 | 2.47 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q2 | 1.47 Million EUR | 0.0% |
| 2023 Q3 | 1.51 Million EUR | 2.17% |
| 2023 Q1 | 1.47 Million EUR | 97.86% |
| 2023 FY | 344 Thousand EUR | -53.95% |
| 2023 Q4 | 1.51 Million EUR | 0.0% |
| 2022 Q1 | 38 Thousand EUR | -90.71% |
| 2022 Q2 | 38 Thousand EUR | 0.0% |
| 2022 Q3 | 747 Thousand EUR | 1865.79% |
| 2022 FY | 747 Thousand EUR | 82.64% |
| 2022 Q4 | 747 Thousand EUR | 0.0% |
| 2021 Q1 | 8.3 Million EUR | 3.88% |
| 2021 FY | 409 Thousand EUR | -94.88% |
| 2021 Q4 | 409 Thousand EUR | 275.23% |
| 2021 Q3 | 109 Thousand EUR | 31.33% |
| 2021 Q2 | 83 Thousand EUR | -99.0% |
| 2020 Q4 | 7.99 Million EUR | 0.0% |
| 2020 Q3 | 7.99 Million EUR | 0.54% |
| 2020 Q1 | 10.68 Million EUR | 48459.09% |
| 2020 FY | 7.99 Million EUR | 36222.73% |
| 2020 Q2 | 7.94 Million EUR | -25.6% |
| 2019 Q3 | 22 Thousand EUR | 0.0% |
| 2019 Q4 | 22 Thousand EUR | 0.0% |
| 2019 FY | 22 Thousand EUR | -99.76% |
| 2019 Q1 | - EUR | 0.0% |
| 2018 FY | 9.3 Million EUR | 37.28% |
| 2017 FY | 6.78 Million EUR | 174.42% |
| 2016 FY | 2.47 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | 68.756% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 99.23% |
| Adocia SA | 4.54 Million EUR | 92.423% |
| Aelis Farma SA | 2.04 Million EUR | 83.203% |
| Biophytis S.A. | 3.11 Million EUR | 88.942% |
| Advicenne S.A. | 15.89 Million EUR | 97.836% |
| genOway Société anonyme | 5.51 Million EUR | 93.767% |
| IntegraGen SA | 642.28 Thousand EUR | 46.441% |
| Medesis Pharma S.A. | 1.2 Million EUR | 71.333% |
| Neovacs S.A. | 650 Thousand EUR | 47.077% |
| NFL Biosciences SA | 39.2 Thousand EUR | -777.484% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 92.104% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | 82.452% |
| Sensorion SA | 1.24 Million EUR | 72.278% |
| Theranexus Société Anonyme | 2.46 Million EUR | 86.02% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | 91.175% |
| TheraVet SA | 1 Million EUR | 65.621% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | 95.019% |
| argenx SE | 15.35 Million EUR | 97.76% |
| BioSenic S.A. | 15.57 Million EUR | 97.791% |
| Celyad Oncology SA | 902 Thousand EUR | 61.863% |
| DBV Technologies S.A. | 4.52 Million USD | 92.399% |
| Galapagos NV | 4.94 Million EUR | 93.042% |
| Genfit S.A. | 62.25 Million EUR | 99.447% |
| GeNeuro SA | 6.49 Million EUR | 94.701% |
| Innate Pharma S.A. | 30.6 Million EUR | 98.876% |
| Inventiva S.A. | 25.61 Million EUR | 98.657% |
| MaaT Pharma SA | 5.42 Million EUR | 93.659% |
| MedinCell S.A. | 52.8 Million EUR | 99.348% |
| Nanobiotix S.A. | 41.66 Million EUR | 99.174% |
| Onward Medical N.V. | 16.3 Million EUR | 97.89% |
| Oryzon Genomics S.A. | 3.45 Million EUR | 90.031% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 99.031% |
| Oxurion NV | 117 Thousand EUR | -194.017% |
| Pharming Group N.V. | 123.65 Million EUR | 99.722% |
| Poxel S.A. | 40.14 Million EUR | 99.143% |
| GenSight Biologics S.A. | 1.04 Million EUR | 67.176% |
| Transgene SA | 17 Thousand EUR | -1923.529% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 99.988% |
| Valneva SE | 132.76 Million EUR | 99.741% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |